GSK’s Blenrep Demonstrates Survival Advantage Over J&J’s Darzalex in Multiple Myeloma Treatment

Clinical Trials Success:
GSK's Blenrep (belantamab mafodotin) has shown significant improvement in progression-free survival (PFS) compared to standard of care combinations in two phase III trials, DREAMM-7 and DREAMM-8, for relapsed or refractory multiple myeloma23.

DREAMM-7 Results:
The DREAMM-7 trial demonstrated a 59% reduction in the risk of disease progression or death and a 43% reduction in the risk of death compared to daratumumab plus bortezomib and dexamethasone3.

DREAMM-8 Results:
The DREAMM-8 trial showed that Blenrep plus pomalidomide and dexamethasone significantly extended PFS compared to bortezomib plus pomalidomide and dexamethasone2.

Regulatory Challenges:
Despite these positive results, Blenrep faces regulatory challenges due to previous setbacks, including the European Medicines Agency not renewing its conditional marketing authorization and GSK withdrawing the drug from the US market after it failed a late-stage trial1.

Safety Concerns:
Ongoing safety concerns, particularly eye toxicity, could limit Blenrep's adoption. In the DREAMM-7 trial, 34% of participants experienced eye-related side effects14.

Market Competition:
The multiple myeloma drug market is highly competitive, with established treatments like CAR T-cell therapies and bispecific antibodies, which could impact Blenrep's market prospects1.

Sources:

1. https://www.fitchsolutions.com/bmi/pharmaceuticals/gsks-blenrep-faces-constrained-market-prospects-due-regulatory-and-competitive-challenges-12-03-2024

2. https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-results-from-dreamm-8-phase-iii-trial-for-blenrep-versus-standard-of-care-combination-in-relapsedrefractory-multiple-myeloma/

3. https://www.gsk.com/en-gb/media/press-releases/dreamm-7-phase-iii-trial-shows-pfs-improvement-and-strong-os-trend-for-blenrep-combo-versus-soc-combo-in-multiple-myeloma/

4. https://www.clinicaltrialsarena.com/analyst-comment/new-hope-for-gsk-once-potential-adc-blockbuster-blenrep/